In recent years, various biomarkers have emerged for diagnosing HCC and predicting patient outcome, including glypican 3 and insulin‐like growth factor (IGF)II mRNA 57, Keap1 and pNrf2 58, 3‐microRNA and AFP 59, CXCL1 60, minichromosome maintenance complex ‐7 61, and IGF1 receptor 62, among others. This evidence concerns the gene IGF2 and hepatocellular carcinoma.